In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis

Nancy J. Olsen, Leigh F. Callahan, Theodore Pincus

Research output: Contribution to journalArticlepeer-review

17 Scopus citations

Abstract

Rheumatoid arthritis (RA) patients whose unstimulated peripheral blood mononuclear cells produce high levels of IgM rheumatoid factor (IgM‐RF) in vitro have more severe disease activity. RA patients being treated with second‐line agents, including gold salts, penicillamine, or methotrexate, tend to be low producers or nonproducers of IgM‐RF in vitro. The possibility that low production or nonproduction of IgM‐RF in vitro may be explained by treatment with second‐line agents alone, irrespective of disease activity, was analyzed in 133 RA patients whose disease status was assessed by multiple laboratory and clinical measures. The results indicate that treatment with second‐line agents and in vitro IgM‐RF synthesis are independently associated with disease activity.

Original languageEnglish (US)
Pages (from-to)1090-1096
Number of pages7
JournalArthritis & Rheumatism
Volume31
Issue number9
DOIs
StatePublished - Sep 1988

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Rheumatology
  • Immunology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'In vitro rheumatoid factor synthesis in patients taking second‐line drugs for rheumatoid arthritis'. Together they form a unique fingerprint.

Cite this